Exactitude Consultancy
Home Report Store Categories Primary Research Consulting Services Blog Contact us About Us Terms & Conditions Privacy Policy
Facebook Twitter Linkedin
+1 (704) 266-3234
Request Free Sample
Home > Life Sciences > Companion Diagnostics Market

Companion Diagnostics Market

Apr 2023

Base Year Value ()

x.x %
x.x %

CAGR ()

x.x %
x.x %

Forecast Year Value ()

x.x %
x.x %

Historical Data Period

Largest Region

Forecast Period

제품별(분석, 키트 및 시약, 소프트웨어 및 서비스), 기술별(중합효소 연쇄 반응, 차세대 시퀀싱, 현장 하이브리다이제이션, 면역조직화학), 적응증별(암, 신경 질환, 감염성 질환, 심혈관 질환), 최종 사용자별(제약 및 생물제약 회사, 계약 연구 기관, 연구소) 및 지역별 동반 진단 시장, 2022년부터 2029년까지의 글로벌 추세 및 예측

Instant access to hundreds of data points and trends

  • Market estimates from 2014-2029
  • Competitive analysis, industry segmentation, financial benchmarks
  • Incorporates SWOT, Porter's Five Forces and risk management frameworks
  • PDF report or online database with Word, Excel and PowerPoint export options
  • 100% money back guarantee
Purchase Options
Download Sample

동반 진단 시장 개요


동반 진단 시장은 2021년부터 2029년까지 13.34% CAGR로 성장할 것으로 예상됩니다 . 2020년 35억 달러에서 2029년까지 132억 3천만 달러 이상으로 성장할 것으로 예상됩니다 .

동반 진단은 환자의 특정 치료에 대한 치료 반응에 대한 정보를 제공하는 체외 검사입니다. 이는 해당 약물 또는 생물학적 제품의 안전하고 효과적인 관리에 필요한 정보를 제공하는 체외 의료 기기입니다. 이 진단 검사는 의사가 특정 치료 제품이 환자에게 유익한지 여부를 판단하고 잠재적인 심각한 부작용이나 위험보다 더 클 수 있는지 여부를 판단하는 데 도움이 됩니다.


사람들 사이에서 다양한 유형의 암이 증가하는 것이 주로 시장 성장을 주도하고 있습니다. 임상 시험의 수가 증가하고 차세대 시퀀싱 에 대한 수요가 증가함에 따라 동반 진단 시장의 성장도 함께 이루어질 것입니다. 이러한 성장을 주도하는 또 다른 요인은 다양한 유형의 약물 생산에서 이 시장 제품의 중요성입니다.


동반 진단 시장은 표적 치료법의 연구개발 증가, 신흥 경제권에서의 관심 증가로 인한 정밀 의학에 대한 수요 증가, 다양한 질환에 대한 새로운 바이오마커 발견, 충족되지 않은 암 치료 수요 증가로 인해 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다.


유전적 시퀀싱과 유전체학에서 진전의 징후가 보이면서, 약물이 사람마다 다른 결과를 낼 수 있다는 것이 이제 널리 받아들여지고 있습니다. 개인의 유전적 특성이나 바이오마커에 대한 더 나은 이해는 '완벽한 개인을 위해 완벽한 시기에 적절한 약물을 적절한 분량으로' 감독하는 행위를 발전시킬 수 있습니다. 약물 및 생물제약 회사는 적절한 경쟁자에게 표적 치료를 제공하기 위해 약물 개발의 초기 단계에서 환자 선택 분석 시스템을 구현하기 위해 끊임없이 노력하고 있습니다. 이는 동반 진단 시장의 성장에 기여합니다.


























































기인하다세부
학습 기간2020-2029
기준년도2022
추정 연도2022
예상 연도2022-2029
역사적 기간2018-2020
단위가치(10억 달러)
분할제공별, 기술별, 표시별, 최종 사용자별, 지역별
레진 테크놀로지로

  • 분석, 키트 및 시약

  • 소프트웨어 및 서비스


기술로

 

  • 중합효소 연쇄 반응

  • 차세대 시퀀싱

  • 현장 하이브리디제이션

  • 면역조직화학


지시에 따라

  • 암

  • 신경계 질환

  • 감염성 질환

  • 심혈관 질환


최종 사용자별

  • 제약 및 바이오제약 회사

  • 계약 연구 기관

  • 실험실


지역별로

  • 북아메리카

  • 아시아 태평양

  • 유럽

  • 남아메리카

  • 중동 아시아 및 아프리카



COVID-19의 도입으로 동반 진단에 대한 소비가 방해를 받았습니다. 또한 주요 시장 참여자들은 COVID-19 팬데믹으로 인해 검사량 감소 및 기타 요인으로 인해 매출이 크게 감소했습니다. 매출 측면에서 시장은 2019년 19.8%에 비해 2020년에 15.1% 성장했습니다.


주요 업체가 창출한 수익은 2020년에 상당히 감소했습니다. 예를 들어, Myriad Genetics, Inc.는 2019년 대비 2020년 분자 진단 수익이 34.5% 감소했다고 보고했습니다. 또한 Abbott Laboratories는 2019년 대비 2020년 핵심 실험실 진단 수익이 4.0% 감소했다고 보고했습니다.


그러나 봉쇄 제한 해제, 많은 국가에서의 재택 명령, 새로운 진단 검사 도입, 공급망 네트워크 재구축은 2021년 검사 회복의 주요 요인이었습니다. 그 결과, 암 진단 검사 재개와 새로운 진단 검사 도입으로 2021년 수요가 증가했습니다.




[캡션 id="attachment_14559" 정렬="정렬센터" 너비="1024"]Companion Diagnostics Market | Exactitude Consultancy
동반 진단 시장 | Exactitude Consultancy
[/표제]

Frequently Asked Questions

• What is the worth of companion diagnostics market?

The companion diagnostics market size had crossed USD 3.5 Billion in 2020 and will observe a CAGR of more than 13.34% up to 2029.

• What are some of the market's driving forces?

Major factors driving the companion diagnostics market growth include the significant growth of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.

• Which are the top companies to hold the market share in companion diagnostics market?

Qiagen, Agilent Technologies, Roche, Abbott Laboratories, Inc., BioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Resonance Health Ltd, Leica Microsystems, Life Technologies, F. Hoffmann-L Roche Ltd., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., Danaher Corporation are the major companion diagnostics market players.

• Which is the largest regional market for companion diagnostics market?

The region's largest share is in North America. Products manufactured in nations like US and Canada that perform similarly and are inexpensively accessible to the general public have led to the increasing appeal.

Companion Diagnostics Market Segment Analysis

The companion diagnostics market is segmented based on products, technology, indication, end user, and region, global trends and forecast.

On the basis of products, the market is segmented into assays, kits & reagents, software & services. Due to increase in demand for kits and reagents, the assays, kits and reagents segment is estimated to lead.

On the basis of technology, the market is segmented into polymerase chain reaction, next-generation sequencing, in situ hybridization, immunohistochemistry.

Based on technology, the pcr segment currently dominates the global market and is expected to do so throughout the forecast period. Cost effectiveness, high sensitivity, and specificity, which can be used for simple automated platforms, are some key factors driving market growth. Furthermore, the pcr, which is another key driver of this segment, can determine the sequencing of unknown etiologies of many diseases. However, the next generation sequencing segment is expected to grow rapidly during the forecast period due to key advantages such as higher sensitivity to detect low-frequency variants, shorter turnaround time for large sample volumes, the ability to sequence hundreds to thousands of genes or gene regions simultaneously, and so on.

On the basis of indication, the market is segmented into cancer, neurological diseases, infectious diseases, cardiovascular diseases.

The cancer segment is currently the largest revenue generator and is expected to grow significantly during the forecast period. Some key factors driving the growth of the cancer segment include increased cancer prevalence, increased r&d activities for cancer, increased unmet needs for cancer treatment, increased number of fda approved companion diagnostics, and increased patient awareness of personalized medicine.

Cancer research has discovered significant differences in gene sequence and expression patterns that can serve as the foundation for targeted therapy. Furthermore, many biomarkers for various cancers have been identified, for which companion diagnostics have been developed. Companion diagnostics are widely used in various types of cancer, including lung cancer, colorectal cancer, breast cancer, and blood cancer, which are the leading causes of death.

On the basis of end user, the market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations, laboratories.

There is no denying that contract research organizations (cros) are becoming more important in the development of companion diagnostics. As the demand for personalized medicine grows, cros are uniquely positioned to assist pharmaceutical and biotechnology companies in developing customized treatments based on a patient's unique genetic makeup.

Companion diagnostics are diagnostic tests used to identify patients who are likely to benefit from a specific treatment. They can also be used to track a patient's response to therapy and make necessary adjustments. Cancer, cardiovascular disease, and infectious diseases are just a few of the conditions that can be treated with companion diagnostics.

[caption id="attachment_14563" align="aligncenter" width="1920"]Companion Diagnostics Market | Exactitude Consultancy
Companion Diagnostics Market | Exactitude Consultancy
[/caption]

Companion Diagnostics Market Players

Qiagen, Agilent Technologies, Roche, Abbott Laboratories, Inc., BioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Resonance Health Ltd, Leica Microsystems, Life Technologies, F. Hoffmann-L Roche Ltd., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., Danaher Corporation are the major Companion Diagnostics market players. Recent Developments: 23 January, 2023: QIAGEN Digital Insights announced launch of their enhanced QIAGEN CLC Genomics Workbench Premium that removes the data-analysis bottleneck of Next-Generation Sequencing by adding analysis speed to analyze and interpret Whole Genome Sequencing, Whole Exome Sequencing and Large Panel Sequencing data. 9 January, 2023: QIAGEN announced of having been completed the acquisition of Verogen, a leader in the use of Next-Generation Sequencing technologies to drive the future of human identification and forensic investigation.

Who Should Buy? Or Key stakeholders

  • Pharmaceutical Companies
  • Research and Development (R&D) Companies
  • Diagnostic Laboratories
  • Government Research Institute
  • Academic Institutes and Universities
  • Investors
  • Regulatory Authorities

Companion Diagnostics Market Regional Analysis

The Companion Diagnostics Market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).

  • North America: includes the US, Canada, Mexico
  • Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
  • Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
  • South America: includes Brazil, Argentina and Rest of South America
  • Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA

North America is expected to lead the global companion diagnostics market. This could explain the high incidence rate of cancer and other chronic diseases, as well as the rising cost of healthcare in the area. Furthermore, market development is expected to drive an increase in the number of healthcare organisations working on generated genomic databases to better understand the human genome, as well as increased research activities in this area using companion diagnostic kits.

The European market for companion diagnostics is expected to be the second-largest during the review period. The expansion of the regional industry is expected to fuel the participation of a large number of companies as well as increased research and development activities aimed at improving personalised drug treatment for cancer patients. Furthermore, rising per capita income increases the preference for personalised treatment, fueling further consumer growth.

Because of the rapidly increasing number of cancer, cardiovascular, and neurological patients, Asia-Pacific is expected to be the fastest growing region. Furthermore, the rising prevalence of infectious diseases has a positive impact on business development. The high prevalence of cancer, increasing proteomics and genomics research, rising research funding, increasing investments by pharmaceutical and biotechnology firms, and rising awareness of personalised therapeutics in many APAC countries are expected to drive the growth of the APAC companion diagnostics market.

The Middle East and Africa market is expected to grow steadily due to an increase in cancer cases and a growing preference for customised drugs. The Middle East and Africa market is expected to grow steadily due to an increase in the number of hospitals and research labs, increased investment by healthcare firms, an increase in cancer cases, and increased drug discovery.

[caption id="attachment_14564" align="aligncenter" width="1920"]Companion Diagnostics Market | Exactitude Consultancy
Companion Diagnostics Market | Exactitude Consultancy
[/caption]

Key Market Segments: Companion Diagnostics Market

  • Companion Diagnostics Market By Offering 2020-2029, (Usd Billion)
  • Assays, Kits & Reagents
  • Software & Services
Companion Diagnostics Market By Technology, 2020-2029, (Usd Billion)
  • Polymerase Chain Reaction
  • Next-Generation Sequencing
  • In Situ Hybridization
  • Immunohistochemistry
Companion Diagnostics Market By Indication, 2020-2029, (Usd Billion)
  • Cancer
  • Neurological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
Companion Diagnostics Market By End User, 2020-2029, (Usd Billion)
  • Pharmaceutical & Biopharmaceutical Companies
  • Contract Research Organizations
  • Laboratories
Companion Diagnostics Market By Region, 2020-2029, (Usd Billion)
  • North America
  • Asia Pacific
  • Europe
  • South America
  • Middle East And Africa
Important Countries In All Regions Are Covered.

Exactitude Consultancy Core Companion Diagnostics Services Key Objectives:

  • Increasing sales and market share
  • Developing new technology
  • Improving profitability
  • Entering new markets
  • Enhancing brand reputation

Key Question Answered

  • What is the expected growth rate of the companion diagnostics market over the next 7 years?
  • Who are the major players in the companion diagnostics market and what is their market share?
  • What are the end-user industries driving demand for market and what is their outlook?
  • What are the opportunities for growth in emerging markets such as Asia-Pacific, Middle East, and Africa?
  • How is the economic environment affecting the companion diagnostics market, including factors such as interest rates, inflation, and exchange rates?
  • What is the expected impact of government policies and regulations on the companion diagnostics market?
  • What is the current and forecasted size and growth rate of the global companion diagnostics market?
  • What are the key drivers of growth in the companion diagnostics market?
  • What are the distribution channels and supply chain dynamics in the companion diagnostics market?
  • What are the technological advancements and innovations in the companion diagnostics market and their impact on product development and growth?
  • What are the regulatory considerations and their impact on the market?
  • What are the challenges faced by players in the companion diagnostics market and how are they addressing these challenges?
  • What are the opportunities for growth and expansion in the companion diagnostics market?
  • What are the service offerings and specifications of leading players in the market?

  1. 소개

    1. 시장 정의

    2. 시장 세분화

    3. 연구 일정

    4. 가정 및 제한



  2. 연구 방법론

    1. 데이터 마이닝

      1. 2차 연구

      2. 1차 연구

      3. 주제별 전문가의 조언



    2. 품질 검사

      1. 최종 검토



    3. 데이터 삼각 측량

      1. 바텀업 방식

      2. 탑다운 접근 방식

      3. 연구 흐름



    4. 데이터 소스



  3. 요약

  4. 시장 개요

    1. 글로벌 컴패니언 진단 시장 전망

      1. 시장 동인

      2. 시장 제약

      3. 시장 기회



    2. 동반 진단 시장에 대한 COVID-19의 영향

    3. 포터의 5가지 힘 모델

      1. 신규 진입자의 위협

      2. 대체품으로부터의 위협

      3. 공급업체의 협상력

      4. 고객의 협상력

      5. 경쟁의 정도



    4. 산업 가치 사슬 분석



  5. 제공 기준 글로벌 동반 진단 시장 (USD 십억 달러), 2020-2029

    1. 분석, 키트 및 시약

    2. 소프트웨어 및 서비스

    3. 핵심 동반 진단 서비스



  6. 기술별 글로벌 동반 진단 시장 (USD 십억), 2020-2029

    1. 중합효소 연쇄 반응

    2. 차세대 시퀀싱

    3. 현장 하이브리드화

    4. 면역조직화학



  7. 지표별 글로벌 동반 진단 시장 (USD 십억 달러), 2020-2029

    1. 암

    2. 신경계 질환

    3. 감염성 질병

    4. 심혈관 질환



  8. GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION), 2020-2029

    1. PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES

    2. CONTRACT RESEARCH ORGANIZATIONS

    3. LABORATORIES



  9. GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION (USD BILLION), 2020-2029

    1. NORTH AMERICA

      1. US

      2. CANADA

      3. MEXICO



    2. SOUTH AMERICA

      1. BRAZIL

      2. ARGENTINA

      3. COLOMBIA

      4. REST OF SOUTH AMERICA



    3. EUROPE

      1. GERMANY

      2. UK

      3. FRANCE

      4. ITALY

      5. SPAIN

      6. RUSSIA

      7. REST OF EUROPE



    4. ASIA PACIFIC

      1. INDIA

      2. CHINA

      3. JAPAN

      4. SOUTH KOREA

      5. AUSTRALIA

      6. SOUTH-EAST ASIA

      7. REST OF ASIA PACIFIC



    5. MIDDLE EAST AND AFRICA

      1. UAE

      2. SAUDI ARABIA

      3. SOUTH AFRICA

      4. REST OF MIDDLE EAST AND AFRICA







  1. COMPANY PROFILES* (BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)

    1. QIAGEN

    2. AGILENT TECHNOLOGIES

    3. ROCHE

    4. ABBOTT LABORATORIES, INC.

    5. BIOMERIEUX

    6. VENTANA MEDICAL SYSTEMS

    7. MYRIAD GENETICS, INC.

    8. RESONANCE HEALTH LTD

    9. LEICA MICROSYSTEMS

    10. LIFE TECHNOLOGIES

    11. HOFFMANN-LA ROCHE LTD.

    12. ILLUMINA, INC.

    13. GUARDANT HEALTH

    14. THERMO FISHER SCIENTIFIC INC.

    15. DANAHER CORPORATION *THE COMPANY LIST IS INDICATIVE




LIST OF TABLES


TABLE 1        GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 2        GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 3        GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 4        GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 5        GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION (USD BILLION) 2020-2029

TABLE 6        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 7        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 8        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 9        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 10      NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 11      US COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 12      US COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 13      US COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 14      US COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 15      CANADA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 16      CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 17      CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 18      CANADA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 19      MEXICO COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 20      MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 21      MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 22      MEXICO COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 23      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 24      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 25      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 26      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 27      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 28      BRAZIL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 29      BRAZIL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 30      BRAZIL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 31      BRAZIL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 32      ARGENTINA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 33      ARGENTINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 34      ARGENTINA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 35      ARGENTINA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 36      COLOMBIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 37      COLOMBIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 38      COLOMBIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 39      COLOMBIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 40      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 41      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 42      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 43      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 44      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 45      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 46      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 47      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 48      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 49      INDIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 50      INDIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 51      INDIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 52      INDIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 53      CHINA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 54      CHINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 55      CHINA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 56      CHINA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 57      JAPAN COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 58      JAPAN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 59      JAPAN COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 60      JAPAN COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 61      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 62      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 63      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 64      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 65      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 66      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 67      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 68      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 69      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 70      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 71      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 72      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 73      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 74      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 75      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 76      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 77      EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 78      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 79      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 80      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 81      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 82      GERMANY COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 83      GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 84      GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 85      GERMANY COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 86      UK COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 87      UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 88      UK COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 89      UK COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 90      FRANCE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 91      FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 92      FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 93      FRANCE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 94      ITALY COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 95      ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 96      ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 97      ITALY COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 98      SPAIN COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 99      SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 100    SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 101    SPAIN COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 102    RUSSIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 103    RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 104    RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 105    RUSSIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 106    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 107    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 108    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 109    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 110    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 111    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 112    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 113    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 114    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 115    UAE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 116    UAE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 117    UAE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 118    UAE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 119    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 120    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 121    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 122    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 123    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 124    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 125    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 126    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 127    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 128    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 129    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 130    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

LIST OF FIGURES


FIGURE 1 MARKET DYNAMICS

FIGURE 2 REPORT TIMELINES: YEARS CONSIDERED

FIGURE 3 BOTTOM-UP APPROACH

FIGURE 4 RESEARCH FLOW

FIGURE 5 GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING USD BILLION, 2020-2029

FIGURE 6 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, USD BILLION, 2020-2029

FIGURE 7 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION, USD BILLION, 2020-2029

FIGURE 8 GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER, USD BILLION, 2020-2029

FIGURE 9 GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, USD BILLION, 2020-2029

FIGURE 10 PORTER’S FIVE FORCES MODEL

FIGURE 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING, USD BILLION, 2021

FIGURE 12 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, USD BILLION, 2021

FIGURE 13 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION, USD BILLION, 2021

FIGURE 14 GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER, USD BILLION, 2021

FIGURE 15 GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, USD BILLION, 2021

FIGURE 16 MARKET SHARE ANALYSIS

FIGURE 17 QIAGEN: COMPANY SNAPSHOT

FIGURE 18 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 19 ROCHE: COMPANY SNAPSHOT

FIGURE 20 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT

FIGURE 21 BIOMERIEUX: COMPANY SNAPSHOT

FIGURE 22 VENTANA MEDICAL SYSTEMS: COMPANY SNAPSHOT

FIGURE 23 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT

FIGURE 24 RESONANCE HEALTH LTD: COMPANY SNAPSHOT

FIGURE 25 LEICA MICROSYSTEMS: COMPANY SNAPSHOT

FIGURE 26 LIFE TECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 27 F. HOFFMANN-L ROCHE LTD.: COMPANY SNAPSHOT

FIGURE 28 ILLUMINA, INC.: COMPANY SNAPSHOT

FIGURE 29 GUARDANT HEALTH: COMPANY SNAPSHOT

FIGURE 30 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT

DOWNLOAD FREE SAMPLE REPORT

Kindly share your specific requirement (if any)
2004

License Type

Single User

US$ 3499

Multi User

US$ 4499

Corporate User

US$ 5499
Buy Now
Enquiry Before Buying

Get Sample to Email

SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click To Email +1 (704) 266-3234 +91 7972605446

WANT TO CUSTOMIZE THE REPORT?

Click Here

Our Clients Speak

We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

Why choose us

Proactive

We manage our resources 24/7 to identify issues and address them before they become problems

Quality & Reliability

We are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach

6 Major regions and 40+ countries level analysis accomplished

Competitive Pricing

Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

In-Depth Database

In-Depth Database

Our Report’s database covers almost all topics of all regions over the Globe.

Recognised Publishing Sources

Recognised Publishing Sources

Tie ups with top publishers around the globe.

Customer Support

Customer Support

Complete pre and post sales support.

Safe & Secure

Safe & Secure

Complete secure payment process.

Talk to Expert

Call for an appointment!

+1 (704) 266-3234

Feel free to message us!

Send an Email

Contact us

ddcde742412eaeabeaf7f82820481462.png
Exactitude Consultancy Plot No. 39, SR, 10-16, NDA Pashan Rd, Bavdhan, Pune, Maharashtra 411021 +1 (704) 266-3234 +91 7972605446 sales@exactitudeconsultancy.com

Quick Links

About Blog Contact Us Sitemap
How to order Delivery Method Return Policy FAQ Privacy Policy Disclaimer Terms and Conditions

We accept

Exactitude Consultancy

2026 © Exactitude Consultancy | All rights reserved

Exactitude Consultancy Email Us
Exactitude Consultancy Contact Us
Exactitude Consultancy +1 (704) 266-3234